Previous 10 | Next 10 |
2024-03-28 09:00:07 ET More on Candel Therapeutics Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Candel Therapeutics Historical earnings data for Candel Therapeutics Financial information for Candel Th...
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024 Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in recurrent high-grade glioma, published in Nature Catalyst-rich 202...
--News Direct-- By Jeremy Golden, Benzinga Among brain tumors, high-grade gliomas are the most frequently diagnosed and fatal. Most of the patients with high-grade glioma will have glioblastoma, a more aggressive form of the cancer. The global burden of high-grade gliomas, which h...
2024-03-06 09:10:00 ET March 6, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage i...
2024-03-06 08:40:19 ET Vancouver, Kelowna and Delta, British Columbia – March 6, 2024 – Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Bi...
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a pos...
--News Direct-- By Jeremy Golden, Benzinga A clinical-stage biopharmaceutical company has been granted Fast Track Designation by the FDA for a first-in-class drug candidate. Focused on developing multimodal biological immunotherapies to help patients fight cancer, Candel Therapeutic...
2024-02-15 09:15:00 ET February 15, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage immunotherapeutics comp...
--News Direct-- By Jeremy Golden, Benzinga A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion. Focused on the development of multimodal biological immunotherapies to help patients fight cancer, Candel Therapeutics...
2024-02-14 08:38:21 ET More on Pre-market losers & stocks. Biodexa stock jumps on allowance of U.S. patent covering Tolimidone Esports Entertainment announces 1-for-400 reverse stock split Seeking Alpha’s Quant Rating on Biodexa Pharmaceuticals His...
News, Short Squeeze, Breakout and More Instantly...
Candel Therapeutics Inc. Company Name:
CADL Stock Symbol:
NASDAQ Market:
Candel Therapeutics Inc. Website:
2024-07-16 20:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Pete...